ALS

ALS

FDA advisers vote against experimental ALS treatment

The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not been shown effective for patients with the fatal, muscle-wasting disease known as ALS, or amyotrophic lateral sclerosis.

This decision highlights the challenges in finding effective treatments for ALS and the importance of rigorous testing and evaluation of potential therapies before they are approved for use in patients.